Abstract:Pancreatic cancer is one of the most aggressive forms of cancer and is the seventh leading cause of cancer deaths worldwide. Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic cancers. Most pancreatic cancers are recalcitrant to radiation, chemotherapy, and immunotherapy, highlighting the urgent need for novel treatment options for this deadly disease. To this end, we screened a library of kinase inhibitors in the PDAC cell lines PANC-1 and BxPC-3 and identified two highly potent molecules: Aurora kinase inhibitor AT 9283 (AT) and EGFR kinase inhibitor WZ 3146 (WZ). Both AT and WZ exhibited a dose-dependent inhibition of viability in both cell lines. Thus, we conducted an in-depth multilevel (cellular, molecular, and proteomic) analysis with AT and WZ in PANC-1 cells, which harbor KRAS mutation and exhibit quasimesenchymal properties representing pancreatic cancer cells as having intrinsic chemoresistance and the potential for differential response to therapy. Elucidation of the molecular mechanism of action of AT and WZ revealed an impact on the programmed cell death pathway with an increase in apoptotic, multicaspase, and caspase 3/7 positive cells. Additionally, the key survival molecule Bcl-2 was impacted. Moreover, cell cycle arrest was observed with both kinase inhibitors. Additionally, an increase in superoxide radicals was observed in the AT-treated group. Importantly, proteomic profiling revealed differentially regulated key entities with multifaceted effects, which could have a deleterious impact on PDAC. These findings suggest potential targets for efficacious treatment, including a possible increase in the efficacy of immunotherapy using PD-L1 antibody due to the upregulation of lactoferrin and radixin. Furthermore, combination therapy outcomes with gemcitabine/platinum drugs may also be more effective due to an increase in the NADH dehydrogenase complex. Notably, protein-protein interaction analysis (STRING) revealed possible enrichment of reactome pathway entities. Additionally, novel therapy options, such as vimentin-antibody--drug conjugates, could be explored. Therefore, future studies with the two kinases as monotherapy/combination therapy are warranted.

Selective and Effective Suppression of Pancreatic Cancer Through MNK Inhibition.

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Progress in developing MNK inhibitors

Activated K‐Ras and INK4a/Arf Deficiency Promote Aggressiveness of Pancreatic Cancer by Induction of EMT Consistent with Cancer Stem Cell Phenotype

Multifaceted Effects of Kinase Inhibitors on Pancreatic Cancer Cells Reveals Pivotal Entities with Therapeutic Implications

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases

Effects of VCP979 Novel P38 Mitogen Activated Protein Kinase Inhibitor on Progression of Pancreatic Cancer in Mouse Model with Diabetic Conditions

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling

Inhibition of PTP1B Blocks Pancreatic Cancer Progression by Targeting the PKM2/AMPK/mTOC1 Pathway

Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer.

Abstract 592: A novel pMEK inhibitor ABM-4095 for the treatment of pancreatic cancer

Targeting Β-Catenin Signaling for Therapeutic Intervention in MEN1-deficient Pancreatic Neuroendocrine Tumours

Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis

Modulation Of Beta-Catenin Signaling By The Inhibitors Of Map Kinase, Tyrosine Kinase, And Pi3-Kinase Pathways

Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

Discovery And Characterization Of Dual Inhibitors Of Mdm2 And Nfat1 For Pancreatic Cancer Therapy

Simultaneous Silencing of XIAP and Survivin Causes Partial Mesenchymal-Epithelial Transition of Human Pancreatic Cancer Cells Via the PTEN/PI3K/Akt Pathway

PP2A Inhibitors Suppress Migration and Growth of PANC-1 Pancreatic Cancer Cells Through Inhibition on the Wnt/β-catenin Pathway by Phosphorylation and Degradation of Β-Catenin